ArticleDEN open2026
Treatment of Hepatocellular Carcinoma Using Endoscopic Ultrasound-guided Radiofrequency Ablation: A Case Series.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA): Are We Getting Evidence-Based Results? A Systematic Review According to the Levels of Evidence.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Recent Development of Endo-hepatology.DEN open · 2027Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is an emerging technique for treating pancreatic and neuroendocrine tumors in patients who are not candidates for surgery. However, there is limited evidence of EUS-RFA in hepatic cancers. The present case series describes five elderly patients with compensated cirrhotic hepatocellular carcinomas (HCCs) treated locally using EUS-RFA. Alpha-fetoprotein levels were reduced in patients after 1 month of the procedure. Computed tomography analysis also reported a reduction in HCCs in patients postoperatively. Repeat computed tomography triple-phase abdomen also showed complete radiological response to treatment in lesions <3 cm. None of the patients reported any procedural adverse event. EUS-RFA offers safe ablation of <3 cm HCC lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.